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Genetic engineering enables the construction of gene man Genome Project (5), efﬁcient and robust produc-
tion and puriﬁcation strategies are necessary (6). For fusions resulting in fusion proteins having the com-
bined properties of the original gene products. Fusion industrial production of recombinant proteins, simple
and fast puriﬁcation methods introduced as an early can be made on either or both sides of the target gene
depending on the speciﬁc application, but the majority unit operation can improve the overall economy of the
process. A powerful puriﬁcation technique made possi- of the described fusion protein systems place the pro-
tein of interest at the C-terminal end of a well-charac- ble by the introduction of genetic engineering is to pu-
rify the target protein by the use of a genetically fused terized fusion partner. Many different applications for
fusion proteins in widespread areas of biotechnology afﬁnity fusion partner. Such fusion proteins can often
be puriﬁed to near homogeneity from crude biological have been reported (1–3), including a facilitated puri-
ﬁcation of the target protein, means to decrease prote- mixtures by a single, and fusion-partner-speciﬁc, afﬁn-
ity chromatography step. olysis of the target protein, display of proteins on sur-
faces of cells and phage, and construction of reporter To date, a large number of different gene fusion sys-
tems, involving fusion partners that range in size from molecules for the monitoring of gene expression and
protein localization as well as to increase the circula- one amino acid to whole proteins capable of selective
interaction with a ligand immobilized onto a chroma- tion half-life of protein therapeutics. However, as pion-
eered by Uhle ￿n and co-workers in 1983 (4), the most tography matrix, have been described. In such systems,
different types of interactions, such as enzyme–sub- frequent application of gene fusions has been for the
purpose of afﬁnity puriﬁcation of recombinant proteins. strate, bacterial receptor–serum protein, polyhisti-
dines–metal ion, and antibody–antigen, have been uti- This review focuses on the use of afﬁnity tag fusions
for detection, puriﬁcation, and immobilization of re- lized (7). The conditions for puriﬁcation differ from sys-
tem to system and the environment tolerated by the combinant proteins. A general overview of commonly
used afﬁnity tags is followed by some recent examples target protein is an important factor for deciding which
afﬁnity fusion partner to choose. In addition, other fac- of speciﬁc applications for afﬁnity tags and a discussion
concerning possible future trends. tors, including protein localization, costs for the afﬁnity
matrix and buffers, and the possibilities of removing
the fusion partner by site-speciﬁc cleavage, should also AFFINITY FUSION PARTNERS
be considered. Numerous gene fusion systems for af-
There is a great interest in developing methods for ﬁnity puriﬁcation have been described in the literature,
fast and convenient puriﬁcation of proteins. For exam- all with different characteristics (3,7–10). Some of the
ple, to facilitate functional and structural studies of most commonly used systems are listed in Table 1, to-
proteins derived from the rapidly growing number of gether with their respective elution condition(s) and
genes coming out of genome programs such as the Hu- agents suitable for speciﬁc detection of expressed fu-
sion proteins.
The introduction of a recognition sequence for a
1 Present address: Pharmacia and Upjohn AB, Department of Bio- chemical agent or a protease between the fusion part-
technology, S-11287 Stockholm, Sweden. ner and the target protein allows for site-speciﬁc cleav- 2 To whom correspondence should be addressed at Department
age of the fusion protein to remove the afﬁnity fusion of Biochemistry and Biotechnology, Kungliga Tekniska Ho ¨gskolan,
Teknikringen 30, S-100 44 Stockholm, Sweden. partner (see below). However, for many applications
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TABLE 1
Commonly Used Afﬁnity Fusion Systems
Size
Fusion partner (kDa) Ligand Detection
a Elution
b
Protein A (Pharmacia Biotech) 31 hIgG Rabbit IgG–peroxidase conjugate Low pH
Z (Pharmacia Biotech) 7 hIgG Rabbit IgG–peroxidase conjugate Low pH
ABP 5–25 HSA HSA–FITC conjugate Low pH
GST (Pharmacia Biotech) 26 Glutathione Anti-GST antibodies Reduced glutathione
poly His (Novagen; Qiagen) 1M e
2 / -Chelator Ni
2/–NTA–alkaline phosphatase Imidazole/Low pH
conjugate
Anti-H6 antibodies
MBP (New England Biolabs) 40 Amylose Anti-MBP antiserum Maltose
FLAG peptide (Kodak) 1 mAb M1 Anti-FLAG M2 mAb EDTA/Low pH
mAb M2 Low pH/FLAG peptide
PinPoint
c (Promega) 13 Streptavidin/Avidin Streptavidin conjugates —
monomeric Avidin Biotin
a Examples of commercially available reagents for detection.
b Most used elution method.
c A 13-kDa subunit of the transcarboxylase complex from Propionibacterium shermanii commercialized as the PinPoint System (Promega).
the afﬁnity tag may be left on the target protein, e.g.: ing novel afﬁnity matrices utilizing an immobilized tar-
get protein (20). (i) to function as immunogens for the generation and
puriﬁcation of antibodies (6,11–13); (ii) when the anal-
ysis of the biological activity of the target protein is Staphylococcal Protein A and Its Derivative Z
unaffected by the afﬁnity fusion partner (14–23); (iii) Staphylococcal protein A (SPA) is an immunoglobu-
for directed immobilization of the target protein lin-binding receptor present on the surface of the gram-
(6,12,20,23–27). positive bacterium Staphylococcus aureus. The strong
In order to study different interactions between bio- and speciﬁc interaction between SPA and the constant
molecules, e.g., protein–protein, protein–DNA (RNA), part (Fc) of certain immunoglobulins (Ig) has made it
it is indeed convenient to have the interacting protein useful for the puriﬁcation and detection of immuno-
immobilized in a directed manner via an afﬁnity tag. globulins in a variety of different applications (31,32).
This strategy has been employed when biomolecular SPA is capable of binding to the constant part of IgG
interactions have been characterized in dedicated in- from a large number of different species including man
struments, i.e., biosensors (27). Furthermore, immobi- (31,33). In addition, SPA has the capacity to bind to a
lization of enzymes can be used to obtain bioreactors limited number of Fab fragments containing certain
or to facilitate removal or reuse of the biocatalyst and VH sequences (34,35). The cloning and sequencing of
to alter the characteristics of the immobilized enzyme the SPA gene revealed a highly repetitive organization
or the intended reaction (23,28,29). Cysteine residues of the protein that could be divided into a signal se-
have been used to achieve directed immobilization quence followed by ﬁve homologous domains (E, D, A,
(24,30), but this strategy has the drawback that added B, and C) and a cell surface anchoring sequence de-
cysteines can be involved in the formation of unwanted noted XM (Fig. 1) (36,37). It was later shown that all
intra- or intermolecular disulﬁdes. Also polyhistidine ﬁve domains of SPA were separately capable of binding
and polyarginine tags have been utilized to achieve a
directed immobilization (25,26), but additional interac-
tions between the afﬁnity matrices used (IMAC or ion-
exchange resins) and the target protein might disturb
the intended orientation of the immobilization. An in-
teresting alternative is to use an in vivo biotinylated
afﬁnity fusion partner for immobilization of the fusion
protein onto streptavidin- or avidin-coated surfaces
(20, 27). The exceptionally strong interaction (Kd 
10
015 M) between streptavidin and biotin ensures a ro-
FIG. 1. Schematic representation of staphylococcal protein A (SPA) bust and efﬁcient immobilization. Furthermore, immo- and the origin of the one-domain SPA analog Z. S, signal peptide
bilization of bi- or multifunctional fusion proteins via (processed during secretion); E, D, A, B, and C, immunoglobulin-
binding domains; XM, cell wall anchoring region. one of its afﬁnity activities is also a strategy for creat-
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IgG (38). The isolation of the gene made it possible to
take advantage of different extensions of the receptor
for use as afﬁnity fusion partners, allowing one-step
IgG-afﬁnity puriﬁcation of target proteins (Table 1)
(4,39,40).
Several additional properties of SPA (or fragments
thereof) have made it particularly suitable as fusion
partner for production of recombinant proteins: (i) SPA
is highly stable against proteolysis in various hosts
FIG. 2. Schematic representation of streptococcal protein G (SPG) (40). (ii) The N- and C-termini of the three-helix bundle
and the extensions of various serum albumin-binding subfragments structure of an individual IgG-binding SPA domain are
described in the text. S, signal peptide (processed during secretion);
solvent exposed (41–44), which favors an independent W, cell wall anchoring region. The regions responsible for serum
folding of a fused target protein and the SPA fusion albumin and immunoglobulin binding, respectively, are marked by
arrows. partner; (iii) SPA does not contain any cysteine resi-
dues that could interfere with the disulﬁde formation
within a fused target protein (36). (iv) SPA is highly
soluble and renatures efﬁciently after having been sub- cocci and is capable of binding to both IgG and serum
albumin (63–65). The structure is highly repetitive jected to denaturants such as urea and guanidinium-
HCl, which facilitates the refolding of SPA fusion pro- with several structurally and functionally different do-
mains (66,67). The regions responsible for the afﬁnities teins from inclusion bodies or the ‘‘reshufﬂing’’ of mis-
folded or multimeric forms of disulﬁde-bridged target to serum albumin and IgG, respectively, are structur-
ally separated, which allowed for the subcloning of proteins (45–49). In addition, SPA fusion proteins can
be produced to high levels within the E. coli cell and fragments displaying serum albumin binding only (Fig.
2) (65). The serum albumin binding region has been still remain soluble (6,18). (v) It has been demonstrated
that it is possible to introduce different protease recog- proposed to contain three binding motifs (ca. 5 kDa
each), of which one has been structurally determined nition sequences accessible for site-speciﬁc cleavage of
SPA fusion proteins to release the target protein showing a three-helix bundle domain, surprisingly sim-
ilar in structure to an IgG-binding domain of SPA (48,50). (vi) The SPA fusion partner is secretion compe-
tent, and SPA fusions can be efﬁciently secreted to the (68,69). The region binds to serum albumins from dif-
ferent species with various afﬁnities and shows strong E. coli periplasm and in some cases also to the culture
medium, using the SPA promoter and signal sequence binding to human serum albumin (HSA) (70). Expres-
sion in E. coli has demonstrated that the region shows (51–55).
To allow chemical cleavage of SPA fusion proteins a high proteolytic stability, is highly soluble, and can
be efﬁciently secreted (6,12,65,71). with both CNBr and hydroxylamine, an engineered do-
main based on domain B lacking methionine was de- Different parts of the region, denoted BB, ABP (albu-
min binding protein) or ABD (albumin-binding domain) signed. In this new domain, designated Z (Table 1), the
glycine residue in a hydroxylamine sensitive Asn–Gly (Fig. 2) have been utilized as fusion partners, allowing
one-step HSA-afﬁnity chromatography puriﬁcation of sequence was replaced by alanine, making it resistant
to either of these chemical agents (Fig. 1) (56). In most fusion proteins expressed either intracellularly or as
secreted proteins (Table 1) (6,12,18,21,22,58,65,71– of the recently constructed ‘‘SPA’’ afﬁnity fusion vec-
tors, constructs with different multiplicities of this Z 74). In addition to E. coli, other hosts such as COS and
CHO cells (75) and gram-positive bacteria (76,77), have domain have replaced the original SPA fusion partner.
Analysis of different repeats of Z binding to IgG showed successfully been used to produce BB or ABP fusion
proteins. that there was no advantage in using more than two
Z domains (24). A number of different expression vec- ABP and protein A (Z) fusion proteins are most con-
veniently eluted from afﬁnity columns using low pH tors for E. coli production of Z or ZZ fusions in which
the fusion protein either is exported (12,57–59) or kept (e.g., acetic acid of pH  3). However, low pH can in
some instances be destructive for target protein func- intracellularly (6,18,48,49,60,61) have been developed.
SPA and ZZ fusion proteins have also been successfully tion and must in such cases be avoided. In addition,
the use of low pH eluents following an initial capture expressed in alternative hosts such as gram-positive
bacteria, yeast, plant cells, Chinese hamster ovary of a fusion protein at physiological pH, could result in
passage of the pH through the isoelectric point (pI)o f (CHO) cells, and insect cells (40,62).
the immobilized protein, which in some cases might
Albumin-Binding Protein from Streptococcal Protein G lead to aggregation. Alternative elution conditions re-
ported for ABP fusion proteins include high pH (pH 12) Streptococcal protein G (SPG) is a bifunctional recep-
tor present on the surface of certain strains of strepto- (75), lithium diiodosalicylate (0.25 M) (72), and heat
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binding region BB, allowing a means to speciﬁcally re-
move the competitor after elution via a second afﬁnity
function. Thus, the excess of competitor present in the
eluate is captured through a simple HSA-afﬁnity chro-
matography step. In addition, the strategy allows also
for the reuse of the ZZ-BB competitor after elution of
the fusion protein from the column. Furthermore, the
ZZ-BB competitor should also be useful for effective
competitive elution of monovalent albumin-binding do-
main fusion proteins.
The inherent properties of the serum albumin-bind-
ing fusion partners could make such fusion proteins of
particular interest for delivery of protein therapeutics,
as well as for administration of subunit vaccines. The
strong and speciﬁc binding to serum albumin has been
proposed to be responsible for the increased in vivo
stability seen for otherwise rapidly cleared proteins
(75,78). Serum albumin, which is the most abundant
protein in serum, has a long half-life itself (19 days in
humans) (79) and could therefore act as a ‘‘stabilizer’’ of
sensitive proteins via a serum albumin-binding fusion
partner. It has been demonstrated that the half-life in
mice of a CD4 fragment (the target receptor for human
immunodeﬁciency virus) could be signiﬁcantly in-
creased by fusion to BB (78). Likewise, fusion to differ-
ent serum albumin-binding fragments of SpG was
shown to increase the serum half-life of human soluble
complement receptor type 1 (sCR1) in rats (75).
The serum albumin-binding region of SpG seems to
have immunopotentiating properties, when used as a
carrier protein genetically fused to a protein immuno-
gen used for immunization (73). Recently, it was dem-
onstrated that a BB fusion protein, BB-M3 containing
a malaria peptide, M3, induced signiﬁcant antibody re-
sponses in mice strains that were nonresponders to
the malaria peptide alone or when fused to a different
afﬁnity fusion partner, suggesting that BB fusion part-
ner has the ability to provide T-cell help for antibody
production (80).
Polyhistidine Tags
In 1975 a new concept for afﬁnity puriﬁcation of pro-
teins was presented by Porath and co-workers (81,82).
The method is based on the interaction between the
side chains of certain amino acids, particularly histi- FIG. 3. Cartoon describing the concept of competitive elution using
an engineered, bifunctional competitor protein. dines, on a protein surface and immobilized transition
metal ions, and is today known as immobilized metal
ion afﬁnity chromatography (IMAC). The metal ions
are immobilized by the use of a chelating agent capable (707C) (23). A general concept for mild elution of Z or
ABD fusion proteins, based on competition, was re- of presenting the metals for binding to the protein. Sev-
eral gene fusion systems employing histidine-rich tags cently devised (Fig. 3) (18). The target protein fused to
a single Z domain is efﬁciently eluted by competition for puriﬁcation of recombinant proteins on immobilized
metal ions have since then been described (Table 1) (9). with a divalent ZZ competitor protein having a more
than 10-fold higher apparent afﬁnity for hIgG. The ZZ Tags, either N- or C-terminal, consisting of consecutive
histidine residues binding selectively to immobilized domains were fused to the divalent serum albumin
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Ni
2/ ions were described by Hochuli and co-workers straints for metal ion binding. Such ‘‘histidine patch’’
thioredoxins could ﬁnd broad use as fusion partners (83). Adsorption of the poly-His-tagged proteins to a
metal–chelate adsorbent was performed at neutral or since they combine two beneﬁcial features, high solu-
bility and the possibility of using afﬁnity chromatog- slightly alkaline pH, at which the imidazole group of
the histidines is not protonated (84). The expressed raphy for puriﬁcation.
fusion proteins were recovered with a purity of more
than 90% in a single step using a Ni
2/–nitrilotriacetic In Vivo Biotinylated Afﬁnity Tags
acid (NTA) adsorbent and elution with low pH or by
competition using imidazole (83,84). The strong binding (Kd  10
015 M) between biotin
and avidin or streptavidin (108–110) is frequently Other research groups have described the use of al-
ternative chelators such as iminodiacetic acid (IDA) used in biochemistry and molecular biology for immo-
bilization and detection purposes. For use in such ap- (27,85–88) or Talon (Clontech) as well as other His-
containing tag sequences such as variants also con- plications, biotinylation of proteins is most frequently
achieved through a covalent coupling of biotin to the taining Trp residues (85,89) or multiple copies of the
peptide Ala–His–Gly–His–Arg–Pro (86). For IMAC protein by the use of biotin-ester reagents that prefer-
entially modify lysine residues (111). However, such puriﬁcation of various His–Trp containing fusion pro-
teins, the use of Co
2/ or Zn
2/ rather than Ni
2/ as the coupling is difﬁcult to direct to a speciﬁc position and
can occur at several residues, some of which might be immobilized metal ion has been shown to lead to less
contamination of E. coli proteins (89). General expres- important for the protein structure and/or activity.
An elegant strategy for site-speciﬁc biotinylation of sion vectors for both intracellular (27,87,90–93) and
secreted production (94,95) of hexahistidine (His6) fu- recombinant proteins during their production was
demonstrated by Cronan, utilizing the in vivo biotiny- sion proteins in E. coli have been developed. Further-
more, His6 sequences have also been employed in the lation machinery of E. coli (112). Analysis of various
extensions of the naturally biotinylated 1.3 S subunit production and puriﬁcation of dual afﬁnity fusions in
E. coli in combination with a modiﬁed S-peptide of ribo- of Propionibacterium shermanii transcarboxylase
(113) showed that a 75-residue fragment was sufﬁ- nuclease A (96,97), the albumin-binding protein ABP
(22), or the GST fusion partner (98). The use of polyhis- cient to serve as substrate for biotinylation. Thus, fu-
sion proteins containing in vivo biotinylated domains tidines as fusion partners for puriﬁcation has been
demonstrated for recombinant fusion proteins pro- could be puriﬁed by afﬁnity chromatography em-
ploying immobilized monovalent avidin (114), and duced in a wide range of host cells other than E. coli:
Saccharomyces cerevisiae (13,99), mammalian cells subsequently eluted with free biotin for mild elution
(112). The stability of the avidin ligand also allows (88,100), and baculovirus-infected Spodoptera frugi-
perda insect cells (101,102). the capture of proteins under denaturing conditions,
such as in the presence of 1% sodium dodecyl sulfate An important advantage of the His6 afﬁnity tag is
the possibility of purifying proteins under denaturing (SDS) or 8 M urea (112). Reusable matrices can also
be obtained by chemical modiﬁcation (nitration) of ty- conditions. Thus, proteins that have aggregated into
inclusion bodies can be dissolved in a suitable agent rosine in the biotin-binding sites of avidin and strep-
tavidin. Such matrices called nitrostreptavidin or ni- such as urea or Gu-HCl and puriﬁed by IMAC. Refold-
ing of the target protein can then be performed without troavidin allow for elution of biotin-containing pro-
teins by free biotin or alkaline pH (pH 10) (115). interference from other proteins (84,103). Further-
more, small afﬁnity tags such as the His6 peptide can Few proteins are naturally modiﬁed by biotin incor-
poration. In E. coli only one such protein, the biotin easily be genetically fused to a target gene by polymer-
ase chain reaction (PCR) techniques (62,104). Also, the carboxyl carrier protein (BCCP) of acetyl-CoA carboxyl-
ase, has been found (116). The biotin is covalently strong interaction between polyhistidine tags and im-
mobilized Ni
2/ ions has been demonstrated to result in attached to a speciﬁc lysine residue, a reaction cata-
lyzed by biotin ligase (BirA) (112,113,117). The C-ter- a directed immobilization of the fused target protein,
allowing protein–protein or protein–DNA interaction minal 101 residues of the E. coli BCCP protein have
been utilized successfully as an afﬁnity handle for pro- studies (25,90,105). However, when attached to recom-
binantly expressed DNA-binding proteins, histidine duction and puriﬁcation of a Fab antibody fragment in
E. coli (20). The fusion protein was secreted into the tails have been reported to inﬂuence the DNA-binding
properties (106). culture medium and then puriﬁed on streptavidin aga-
rose beads, resulting in a simultaneous directed immo- An interesting extension of the IMAC technology
has been described by Lu and co-workers (107). Using bilization of the antibody fragment allowing one-step
immunoafﬁnity puriﬁcation of a recombinant human the solubilizing E. coli thioredoxin protein as presen-
tation scaffold, histidine residues were introduced at tumor necrosis factor a (TNF) fusion protein. If desired,
biotinylated proteins bound to streptavidin can be different positions that satisﬁed the geometrical con-
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eluted by boiling in an SDS–urea solution (118). In recombinant proteins using BCCP or shorter tags as
fusion partners, coexpression of the biotin ligase and/ addition to the BCCP and the P. shermanii proteins,
similar proteins from Klebsiella pneumoniae and Ara- or addition of biotin to the growth medium have proven
efﬁcient (20,122). bidopsis thaliana have been used to produce biotin-
modiﬁed fusion proteins in E. coli (112,119). The 1.3 S
subunit of P. shermanii transcarboxylase has also been Glutathione S-Transferase
described to function as a biotinylated fusion partner The glutathione S-transferases (GST) are a family of in recombinant Semliki Forest virus-infected baby enzymes that can transfer sulfur from glutathione to hamster kidney (BHK) and CHO cells (120). substances such as nitro and halogenated compounds, From a combinatorial library of short peptides, se- leading to their detoxication (127). Many mammalian quences capable of mimicking the normal BirA sub- GSTs can be puriﬁed by afﬁnity chromatography using strate were found using an elegant selection strategy the immobilized cofactor glutathione, followed by com- based on fusion of the peptides to a plasmid binding petitive elution with reduced glutathione (128). Based lac repressor protein (121). A family of sequences (ca. on this speciﬁc interaction, a gene fusion system for E. 13 aa) were found to be in vivo biotinylated at a central coli expression was developed by Smith and co-workers invariant lysine residue and could replace the larger in (129), using GST from the parasitic helminth Schisto- vivo biotinylated fusion partners used earlier by other soma japonicum (Table 1). They demonstrated that a groups. Recently, such short tags have found use in number of eukaryotic proteins fused to the C-terminus different puriﬁcation and immobilization situations of GST could efﬁciently be puriﬁed from a crude E. (27,122). coli lysate by glutathione-afﬁnity chromatography. In An alternative small afﬁnity tag (nonbiotinylated) addition, cleavage sites for the proteases thrombin and that binds to streptavidin has been found in a peptide blood coagulation factor Xa had been introduced to library screened for peptides that mimic biotin (123). allow removal of the GST fusion partner (129). It has A nine-amino-acid streptavidin-binding peptide termed been demonstrated that GST fusion proteins can be strep-tag was selected from the library and used as a renaturated from inclusion bodies after solubilization C-terminal afﬁnity fusion partner for puriﬁcation of an using 6 M Gu-HCl and subsequently puriﬁed by gluta- E. coliexpressed antibody Fv fragment by streptavidin- thione-afﬁnity chromatography (130). Recently, a se- afﬁnity chromatography. The fusion protein was com- ries of vectors was described allowing either N- or C- petitively eluted with the biotin analog iminobiotin, terminal fusion of a target protein to GST for produc- which allowed for column regeneration by washing tion in E. coli (131). Furthermore, two vectors have with the equilibration buffer. Such mild elution condi- been developed that allow, in addition to N- or C-termi- tions (diaminobiotin) have also been used in the strep- nal fusion to GST, site-speciﬁc in vitro
32P labeling of tavidin-afﬁnity chromatography puriﬁcation of various the fusion protein after glutathione-afﬁnity puriﬁca- membrane proteins captured via strep-tag fused Fv tion, employing a protein kinase recognizing an intro- fragments (124). Recently, an improved version of the duced substrate sequence (132). The GST fusion part- peptide, strep-tag II, was described (125). In contrast ner has also been used as an N-terminal constituent to the original peptide, strep-tag II has the potential in a dual afﬁnity fusion approach, in combination with to retain its streptavidin-binding activity when placed a His6 tag at the C-terminus of a tripartite fusion pro- at positions other than the C-terminus. tein (98). Furthermore, expression vectors have been A possible complication associated with avidin/strep- constructed for production of GST fusion proteins in tavidin-afﬁnity chromatography of in vivo biotinylated insect cells, S. cerevisiae, and COS-7 cells. (133–136). proteins is that any free biotin should preferentially be A possible complication associated with the GST fusion removed before loading the cell lysate onto the column, system is the use of reduced glutathione (a reducing to avoid blocking of the ligand. In addition, if not re- agent) for elution, which can affect target proteins con- moved in a ﬁrst puriﬁcation step, biotinylated host pro- taining disulﬁdes (137). teins may be copuriﬁed with the biotinylated target
protein. Recently, this problem was circumvented us-
FLAG Peptide ing a combined afﬁnity tag that enabled removal of
biotin and BCCP by employing a ﬁrst HSA-afﬁnity An afﬁnity gene fusion system that has become pop-
ular in recent years is the so-called FLAG system, chromatography step prior to immobilization of the af-
ﬁnity fusion protein onto a streptavidin surface (27). A based on the fusion of an eight-amino-acid peptide to
the target protein for immunoafﬁnity chromatography similar approach was described for the production of a
BCCP-ﬁreﬂy luciferase fusion protein in which a His6 on immobilized monoclonal antibodies. The FLAG pep-
tide sequence (Asp–Tyr–Lys–Asp–Asp–Asp–Asp– tag was also included for IMAC puriﬁcation, prior to
immobilization of the fusion protein onto avidin-coated Lys) is hydrophilic and contains an internal enteroki-
nase cleavage recognition sequence (Asp–Asp–Asp– surfaces (126). To increase the fraction of biotinylated
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Asp–Lys) (138). Monoclonal antibodies to the FLAG bodies followed by amylose-afﬁnity puriﬁcation has
been demonstrated (148). sequence were obtained after immunization of mice
with a FLAG fusion protein. One monoclonal antibody
(M1) was found to bind to FLAG fusion proteins in a SITE-SPECIFIC CLEAVAGE OF FUSION PROTEINS
calcium-dependent manner, which allowed gentle elu-
For certain applications it is necessary to remove the tion by the addition of a chelating agent (138,139). A
afﬁnity fusion partner after puriﬁcation. For example, limitation of the M1 antibody is that it can only bind
a fusion partner can cause unwanted immune re- the FLAG peptide when located at the extreme N-ter-
sponses, alter the properties, or complicate a structural minus of the fusion protein. This limits the use of the
determination of a fused target protein. Several meth- M1 antibody to the puriﬁcation of fusions exposing an
ods have been described for site-speciﬁc cleavage of fu- N-terminal FLAG peptide, such as after removal of a
sion proteins based on chemical or enzymatic treat- signal peptide from a secreted FLAG fusion. Recently,
ment of the fusion protein (9,149) and some relevant it was found that the M1 antibody binds with almost
examples are listed in Table 2. the same afﬁnity to a shortened version of the FLAG
Chemical cleavage methods are relatively inexpen- peptide, consisting only of the ﬁrst four amino acids
sive, but the rather harsh reaction conditions may lead (Asp–Tyr–Lys–Asp) (140). Alternatively, a different
to protein denaturation or amino acid side chain modi- monoclonal antibody (M2), capable of binding to the
ﬁcations of the target protein. Furthermore, the chemi- FLAG peptide also if it is preceded by a methionine at
cals are relatively unspeciﬁc, which can lead to un- the N-terminus or fused to the C-terminus of the target
wanted cleavages inside the target protein (149). Enzy- protein, is available (141). However, the M2 antibody
matic methods are preferred to chemical methods interacts with the FLAG peptide in a non-calcium-de-
because they are generally more speciﬁc and the cleav- pendent manner and a fusion protein can therefore not
age can usually be performed under mild conditions be eluted with a chelating agent. Instead, low pH or
(Table 2) (50,149). competition with an excess of synthetically produced
After cleavage, the released afﬁnity tag can be cap- FLAG peptide is used (Table 1) (141). Different hosts
tured by passage of the cleavage mixture over an afﬁn- havebeen usedfor production of FLAG fusion proteins,
ity matrix while the target protein is obtained in the including E. coli, S. cerevisiae(138), recombinant bacu-
ﬂowthrough. However, in such schemes the protease is lovirus-infected S. frugiperda insect cells (101), and
still left with the target protein and must be removed COS-7 cells (142).
to obtain a pure target protein. To circumvent this,
afﬁnity-tagging of the protease has been employed in
Maltose-Binding Protein order to easily remove the protease after cleavage (see
below) (19,22,153). E. coli maltose-binding protein (MBP), the product
of the mal E gene, is exported to the periplasmic space,
where it binds speciﬁcally with high afﬁnity to maltose SPECIFIC EXAMPLES AND POSSIBLE FUTURE TRENDS
or maltodextrins for subsequent transport of these sug- OF AFFINITY TAG APPLICATIONS
ars across the cytoplasmic membrane (143). MBP can
Combined Afﬁnity Tags be puriﬁed in a single step by afﬁnity chromatography
on resins containing cross-linked amylose followed by A common problem in heterologous gene expression
is proteolytic degradation. Using an afﬁnity fusion strat- competitive elution with maltose (144). This fact to-
gether with the low cost for amylose resins, mild puri- egy, eventual degradation products of the target protein
are copuriﬁed with the full-length fusion protein. Gene ﬁcation conditions, and the fact that MBP does not
contain any cysteine residues that can interfere with fusions can in some cases be used to stabilize labile
proteins, but single fusions have shown limited stabiliz- disulﬁde bond formation within the target protein led
to the development of an expression system for MBP ing effects (154). However, it has been observed that
dual afﬁnity approaches can have a stabilizing effect on fusion proteins in E. coli allowing afﬁnity puriﬁcation
under mild conditions (Table 1) (145). Vectors for both several proteolytically sensitive proteins compared to
single fusions (154). Employing a dual afﬁnity approach, intracellular and secreted production have been devel-
oped (14,145). The vectors designed by Guan and co- as ﬁrst described for the production of the peptide hor-
mone insulin-like growth factor II (58), two different workers were further developed by the introduction of
a cleavage recognition sequence for the factor Xa prote- afﬁnity fusion partners are fused at each end of the
target protein. This allows for two successive afﬁnity ase at the C-terminus of MBP to allow release of a
target protein fused to MBP (146). Recently, expression puriﬁcation steps to obtain proteins that by deﬁnition
only contain both tags and therefore also the central vectors allowing translational fusions to MBP in all
reading frames were presented (147). The possibility target protein (Fig. 4) (58). Several other combinations
of afﬁnity tags have been used in various dual afﬁnity of renaturing an MBP fusion protein from inclusion
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TABLE 2
Examples of Methods for Site-Speciﬁc Cleavage of Afﬁnity Fusion Proteins
Cleavage agent Fusion protein Cleavage speciﬁcity
a Cleavage conditions Reference
Chemical agents
CNBr b-gal-somatostatin -XM f X- 70% formic acid, RT 150
Hydroxylamine ZZ-IGF-I -XN f GX- pH 9, 457C5 3
Enzymes
Enterokinase FLAG–interleukin-2 -X(D)4K f X- pH 8.0, 377C 138
Factor Xa MBP–paramyosin -XIEGR f X- pH 7.2, RT 146
Thrombin GST–Ag63 -XLVPR f GSX- pH 8.0, 257C 129
H64A subtilisin ZZ–PTH -XFAHY f X- pH 8.6, 377C 151
IgA protease MS2–His6–FV -XPAPRPP f TX- pH 7.4, 377C 152
GST
b–protease 3C His6–PKCI -XLETLFQ f GX- pH 8.2, 47C1 9
ABP–protease 3C–His6 ABP–DTaq -XLEALFQ f GPX- pH 8.0, RT 22
Note. Abbreviations used: CNBr, cyanogen bromide; b-gal, b-galactosidase; IGF-I, human insulin-like growth factor I; PTH, human
parathyroid hormone; MS2, bacteriophage MS2 polymerase; PKCI, protein kinase C inhibitor; RT, room temperature.
a X  unspeciﬁc amino acid.
b Also His6–protease 3C.
fusion concepts (97,98,122,155). Thus, the dual afﬁnity Recently, a new afﬁnity fusion partner based on the
concept of combined afﬁnity tags was described (27). A approach points out the advantage, for certain applica-
tions, of using a combination of different afﬁnity tags. general expression vector for N-terminal fusion to an
afﬁnity tag combination consisting of an in vivo biotin- Although a multitude of systems have been de-
scribed, no single afﬁnity fusion strategy is ideal for all ylated sequence (Bio), a hexahistidine (His6) sequence,
and the albumin-binding protein (ABP) was con- expression or puriﬁcation situations. For example, a
fusion to afﬁnity tags derived from normally intracellu- structed (27). Fusion to the Bio–His6–ABP afﬁnity tag
allows the use of several commercial agents for detec- lar proteins (e.g., the b-galactosidase system) is not
applicable when secretion of the product into the per- tion, the possibility of puriﬁcation under both native
iplasm or culture medium is desired. Further, if the
puriﬁcation has to be performed under denaturating
conditions, protein ligands such as monoclonal antibod-
ies (mAbs; e.g., anti-FLAG M1 and M2 mAbs) are likely
to be unsuitable. Instead, a combination of afﬁnity fu-
sion domains could be introduced into a single fusion
partner to obtain general expression vectors for afﬁnity
gene fusion strategies, applicable in several situations.
Such composite fusion partners consisting of several
independent afﬁnity domains could potentially be used
for different detection, puriﬁcation, and immobilization
purposes, employing the afﬁnity function most suitable
for the situation. However, the afﬁnity domains in-
cluded should be carefully chosen so that they do not
functionally interfere with each other, and each moiety
should be able to withstand the puriﬁcation conditions
dictated by the afﬁnity domain requiring the harshest
afﬁnity chromatography conditions. For instance, if de-
naturating conditions are used, as in IMAC puriﬁcation
of proteins containing, e.g., a hexahistidine sequence
solubilized from inclusion bodies by urea or Gua-HCl,
the other included afﬁnity domains should not be irre-
versibly denatured during this step, which otherwise
may cause aggregation in subsequent renaturation
steps. A further advantage of using combined afﬁnity FIG. 4. The dual afﬁnity fusion concept. The target protein is pro-
tags is that different methods may be used for the de- duced as ﬂanked by two different afﬁnity domains and puriﬁed using
two consecutive afﬁnity chromatography steps. tection and immobilization of the fusion protein.
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and denaturating conditions, and an option to choose
from three strong afﬁnity interactions for immobiliza-
tion. In addition, the ABP part of the afﬁnity tag is
soluble and effectively refolded after denaturation,
which can be an advantage during an eventual refold-
ing of the fused target protein. The use of this particu-
lar combination of afﬁnity tags also demonstrates the
advantage of consecutive afﬁnity puriﬁcation steps for
a certain application. Using the ABP–HSA interaction
as the ﬁrst puriﬁcation, removal of biotinylated host
proteins and biotin was possible. This allowed for im-
mobilization of the Bio–His6–ABP afﬁnity tag onto a
streptavidin chip in a Biacore instrument for biospeciﬁc
analysis in the next step. Consecutive afﬁnity domains
have also been used as C-terminal fusion partners for
the evaluation of the best afﬁnity puriﬁcation method
for a rat neurotensin receptor (122).
Afﬁnity-Tagged Proteases for Site-Speciﬁc Cleavage
In gene fusion strategies for the production of native
proteins, efﬁcient means for site-speciﬁc cleavage of the
fusion protein and subsequent removal of the afﬁnity
fusion partner are needed. In addition, when enzymatic
strategies for cleavage are employed, strategies for the
removal of the protease itself must be developed. Spe-
cial consideration must be taken if the target protein
itself has to be further processed to give the desired
ﬁnal product (48,49). Careful upstream design of the
fusion protein construct using genetic strategies can
greatly facilitate the subsequent puriﬁcation of the tar-
get protein and also allow for integrated systems in-
volving coprocessing of the protein and efﬁcient re-
moval of the afﬁnity fusion partner as well as the prote-
FIG. 5. The afﬁnity fusion protease concept used in the puriﬁcation ase used for cleavage (22,49).
of DTaq DNA polymerase. For general use in site-speciﬁc cleavage of fusion pro-
teins comprising relatively large target proteins, prote-
ases such as trypsin, which recognizes basic arginine and the released afﬁnity fusion partner by simple af-
and lysine residues, are not ideal, because these amino ﬁnity chromatography steps. In addition, the desired
acids generally occur in proportion to protein size. Al- amount of protease to ensure efﬁcient cleavage may
ternative enzymes for broader use in biotechnological be added, since the protease is easily removed after
applications should preferably be highly speciﬁc prote- cleavage.
ases, easy to produce by recombinant means in large Recently, a different afﬁnity-tagged protease, con-
scale. Interesting candidate enzymes can be found in sisting of coxsackievirus 3C (3C
pro) fused to the serum
human picornaviruses, whose maturation relies on the albumin-binding ABP at the N-terminus and His6 at
site-speciﬁc cleavage of a large polyprotein precursor the C-terminus (Table 2), was produced in E. coli and
to yield the viral components. Some of these proteases used for the production of a truncated Taq DNA poly-
have been described to be functionally produced at high merase (DTaq), according to the principle described in
levels in bacterial expression systems (19,156), which Fig. 5 (22). The heat-stable polymerase was produced
also would facilitate the production of variants con- as an ABP–DTaq fusion protein having a 3C
pro cleav-
structed by protein engineering. For example, a kit con- age site introduced between the two protein moieties.
taining the 3C protease of rhinovirus (Table 2) fused After HSA-afﬁnity puriﬁcation and heat elution of
to an afﬁnity tag (GST) to be used for speciﬁc cleavage ABP–DTaq, the fusion was cleaved using the afﬁnity-
of target GST-afﬁnity fusion proteins was recently pre- tagged protease ABP–3C
pro–His6, which allowed for
sented (19, PreScission system, Pharmacia Biotech). the recovery of nonfused, fully active DTaq after pas-
sage of the cleavage mixture over an HSA column (22). This enables removal of the afﬁnity-tagged protease
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FIG. 6. Schematic description of the afﬁnity immobilization strategy for Taq DNA polymerase used to achieve hot-start PCR. (A) The
TagTaq fusion protein containing Taq DNA polymerase fused to the Bio–His6–ABP afﬁnity tag. (B) The principle for reactivation of the
inactive, immobilized TagTaq fusion protein through heat-mediated release from the afﬁnity resin.
Furthermore, an afﬁnity fusion protease can also fa- However, the ABP–HSA interaction was shown to be
disrupted at elevated temperatures (707C), resulting cilitate the on-column cleavage of an afﬁnity fusion pro-
tein immobilized onto an afﬁnity column in cases in in a restored DNA polymerase activity of released Taq
DNA polymerase fusion protein. This concept for con- which the afﬁnity ligand is insensitive to the protease
(19,22). Recently, a novel system for simultaneous af- trolling the activity of the Taq DNA polymerase was
demonstrated to be of practical use to achieve a hot- ﬁnity puriﬁcation and on-column cleavage of afﬁnity
fusion proteins was described (157,158; Impact I Sys- start PCR procedure when it is desired to suppress the
DNA polymerase activity until temperatures at which tem, New England Biolabs). In this system the target
protein is fused to a fusion partner consisting of a modi- unspeciﬁc annealing of PCR primers is eliminated are
reached. The afﬁnity-immobilization concept for hot- ﬁed protein splicing element (intein domain) from S.
cerevisiae fused to a chitin-binding afﬁnity tag. After a start PCR was successfully used in full multiple-cycle
PCR ampliﬁcation and was shown to eliminate arti- one-step afﬁnity immobilization of the fusion protein
on a chitin-containing column, free target protein can factual primer–dimer products in the ampliﬁcation of
the human oncogene K-ras gene, in contrast to stan- be eluted after induction (/47C, reducing conditions)
of the speciﬁc proteolytic activity of the intein domain, dard ampliﬁcation protocols. Noteworthy was that the
ABP-afﬁnity fusion partner was still functional after which itself remains immobilized via the chitin-binding
domain (on-column cleavage). 30 PCR cycles, allowing post-PCR reimmobilization of
the Taq DNA polymerase fusion protein onto fresh
HSA–Sepharose and facilitating the removal of the Heat-Mediated Activation of an Afﬁnity-Immobilized
DNA polymerase from reaction mixtures after PCR. Taq DNA Polymerase
Further studies are needed to determine if this concept
Immobilization of enzymes has proven to be a useful for modulating biological activity can also be applied
procedure for many applications, due to altered charac- by using other tags and for other widely used enzymes
teristics of the immobilized enzyme compared to its (e.g., reverse transcriptase).
soluble counterpart (28). One practical application
where such differential activities are utilized was re- Afﬁnity-Assisted in Vivo Folding
cently described in which a heat-mediated release of
an afﬁnity-immobilized recombinant Taq DNA poly- A new concept for improving the fraction of correctly
folded recombinant insulin-like growth factor I (IGF-I) merase (TagTaq) was used to create a so-called hot-
start PCR procedure (23). Taq DNA polymerase was was recently presented (21). It was demonstrated that
coexpression of a speciﬁc binding protein, IGF-binding produced in E. coli as fused to the multifunctional Bio–
His6–ABP tag (see above and Ref. (27)) for afﬁnity pu- protein type 1 (IGFBP-1), signiﬁcantly increased the
relative yield of IGF-I having native disulﬁde bridges riﬁcation and immobilization. HSA-afﬁnity immobili-
zation of the fusion employing the ABP moiety resulted when expressed in a secreted form in E. coli. In addi-
tion, a glutathione redox buffer was added to the in a deactivation of the Taq DNA polymerase (Fig. 6).
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as research tools for detection, puriﬁcation, and immo-
bilization of recombinant proteins expressed in bacte-
ria, yeast, insect cells, plants, and mammalian cells.
However, on an industrial scale the use of afﬁnity fu-
sions to facilitate bioprocessing of recombinant pro-
teins has not yet been widely performed. The main
reason for this is most likely due to the fact that there
has been a demand to produce heterologous proteins
in a native form in the ‘‘ﬁrst generation’’ of recombinant
products. Afﬁnity fusion strategies thus introduce an
additional problem into the downstream processing,
since a site-speciﬁc cleavage is needed. This review
points out new strategies based on afﬁnity fusions,
such as the use of afﬁnity-tagged proteases and afﬁnity
assisted in vivo folding, which would facilitate down-
stream bioprocessing by circumventing some of the
problems related to proteolytic cleavage of fusion pro-
teins, and thus decrease overall production costs. Such
strategies could potentially be implemented in the bio-
pharmaceutical industry in the near future. For pro-
tein-level characterization of the immense number of
genes or gene fragments emerging from various ge-
nome projects, afﬁnity fusion strategies could facilitate FIG. 7. The principle of afﬁnity assisted folding used to improve
the yield of correctly folded recombinant IGF-I in E. coli via coexpres- automated handling of small-scale protein puriﬁcation
sion of an afﬁnity-tagged IGF-I speciﬁc binding protein. The afﬁnity from cell lysates using established 96-well formats
tag was subsequently used for efﬁcient and selective recovery of the (159). We believe that the applications described in this
native folding form of the target protein.
review make it evident that afﬁnity fusion strategies
will ﬁnd even broader use in the near future.
growth medium to enhance formation and breakage of
disulﬁde bonds in the periplasm of the bacteria. In the ACKNOWLEDGMENT
presented example, both IGF-I and IGFBP-1 were pro-
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manuscript. cation of in vivo assembled heterodimers by different
methods (21).
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